Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: Pediatr Infect Dis J. 2009 Aug;28(8):717–723. doi: 10.1097/INF.0b013e31819f1f50

Table 1.

Description of simulation cohorts.

Therapeutic
Goal		 BGA
(wk)* 		PNA on
day 1* 		Serum
creatinine
mg/dl		 Dose
(mg/kg)		 Interval
(hours)		 Duration
(days)		 PK/PD Target #
Treatment IC
very preterm		 25
(23–29)		 21
(1–50)		 <1.3 6–12 24–48 14 90 % with AUC>400
Median AUC 600–800
AUC/MIC>50 for MIC≤8
Treatment IC
late preterm-term		 35
(30–40)		 21
(1–50)		 <1.3 6–12 24 14 90 % with AUC>400
Median AUC 600–800
AUC/MIC>50 for MIC≤8
Early Prevention
from birth		 25
(23–29)		 2
(1–5)		 <1.3 3–6 24–96 42 None available,
summarize exposure with
concentration time profile,
AUC, and T>MIC
Late Prevention
during high risk		 25
(23–29)		 21
(7–50)		 <1.3 3–6 24–72 21

IC, invasive candidiasis

*

median (range), wk (week), BGA (gestational age at birth in weeks), PNA (post natal age on 1st day of fluconazole treatment)

#

AUC, area under the concentration curve at steady state per 24 hour dosing interval (mg*hour/L). T>MIC is the percent of dosing interval time that the fluconazole concentration is maintained above the MIC of the Candida species.